US biotechnology company Regeneron Pharmaceuticals has filed a Federal Court challenge after losing its opposition to a patent application by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.
A Sydney-based law firm has over 200 lawsuits in the pipeline against medical professionals across the country seeking compensation for injuries caused by allegedly dangerous pelvic mesh implants.
Ariosa Diagnostics has asked the Full Federal Court to hear its challenge to a ruling that its Harmony prenatal test infringed Sequenom’s patent for a prenatal genetic test, saying the court’s judgment was attended by “sufficient doubt”.
Global pharmaceutical firm Pfizer is mulling an application to stay a lawsuit by Merck Sharp & Dohme seeking to invalidate a patent related to the blockbuster Prevnar 13 vaccine as it awaits the outcome of similar proceedings in the US.
AFT Pharmaceuticals has challenged a Federal Court decision that found its Maxisegic ads were misleading and deceptive, saying the judge “set the bar too high” by requiring it to prove there was an adequate scientific foundation for its painkiller representations.
Online healthcare platform HealthEngine is facing legal action by the Australian Competition and Consumer Commission, accused of hiding 17,000 negative reviews, altering thousands of other reviews and selling patient’s personal data to insurers.
The plaintiffs in The Cosmetic Institute class action over allegedly botched breast implants will argue a former director of the company was the mastermind behind the ‘one size fits all’ business model, after the business went into liquidation and stopped participating in litigation.
A judge has warned the parties in The Cosmetic Institute class action over allegedly botched breast implants to ensure group members’ rights are prioritised, following a push for an early class closure amid doctor-patient confidentiality concerns.
US biotechnology firm Regeneron Pharmaceuticals has lost its opposition to a proposed patent by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.
A six-week trial set to start in October in the cartel case against mobility equipment provider Country Care Group has been vacated and rescheduled to next year, as the judge overseeing the case quipped that he was either the “canary or the guinea pig” in the landmark criminal proceeding.